MedElevator Войти в исследования
← Поиск публикаций

DOI 10.7759/cureus.88412

Медицинская библиотека · Cureus · 2025

Consensus on the Use of Mefenamic Acid in Pediatric Practice (MAPP): Perspectives From Indian Pediatricians.

Pai Uday, Venkata Ravishankar A, Shah Abhay, Gupta Alok, Clement Antony, Wadhwa Arun, Kumar Ashwani, Somasundaram A, Charde Girish, Joshi K K, Sanklecha Mukesh, Suresh Kumar Mylapore V, Gokhale Praveen, Agarwal Rajeev, Shah Raju, Chhabra Ritesh, Niranjan Sanjay, Dudhgaonkar Shilpa, Surampudi Srikrishna, Nayak Sumitha, Borkar Vibhor V

СтатьяОбзорПеревод в очереди

Аннотация

Fever and pain are among the most common reasons for pediatric consultations, requiring effective and safe management strategies. Mefenamic acid, a well-established member of the nonsteroidal anti-inflammatory drug (NSAID) class, offers distinct advantages due to its unique pharmacological profile, including preferential cyclooxygenase-2 (COX-2) inhibition, E-type prostanoid (EP) receptor blockade, and nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome inhibition. These properties enable it to address both inflammatory and non-inflammatory fevers, providing comprehensive symptom relief. Despite its proven efficacy, the absence of pediatric-specific guidelines and perceived concerns about safety have limited its routine use in pediatric practice. This consensus paper, developed through a structured modified Delphi process involving 21 expert pediatricians across India, aims to address these gaps. The paper evaluates the safety, efficacy, and clinical applications of mefenamic acid, providing evidence-based best-practice recommendations. Highlights include its superior antipyretic efficacy compared to paracetamol and ibuprofen, with preclinical and limited clinical data suggesting potential antiviral activity, and a possible role in the management of febrile seizures and inflammatory conditions. While mefenamic acid demonstrates a favorable safety profile with appropriate use, further research is necessary to strengthen the evidence on long-term safety and expand its therapeutic scope. This consensus provides a comprehensive framework for optimizing the use of mefenamic acid in pediatric practice, ensuring improved patient outcomes. The long-term safety of mefenamic acid in children is still unclear, due to the limited availability of robust, longitudinal safety data. Future research should prioritize well-powered clinical trials, particularly in children aged six months to five years, using standardized outcome measures and long-term follow-up protocols. Addressing these evidence gaps is important to inform safe and effective use in pediatric practice.

Для цитирования: Pai Uday, Venkata Ravishankar A, Shah Abhay, Gupta Alok, Clement Antony, Wadhwa Arun, Kumar Ashwani, Somasundaram A, Charde Girish, Joshi K K, Sanklecha Mukesh, Suresh Kumar Mylapore V, Gokhale Praveen, Agarwal Rajeev, Shah Raju, Chhabra Ritesh, Niranjan Sanjay, Dudhgaonkar Shilpa, Surampudi Srikrishna, Nayak Sumitha, Borkar Vibhor V. Consensus on the Use of Mefenamic Acid in Pediatric Practice (MAPP): Perspectives From Indian Pediatricians.. Cureus. 2025. DOI: 10.7759/cureus.88412.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.